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Objective  To evaluate the prevalence and risk factors of peripheral neuropathy in patients with rheumatoid 
arthritis (RA) treated with lefl  unomide (LEF) by quantitative sensory testing (QST).
Method  A total of 94 patients were enrolledin this study, out of which 47 patients received LEF. The other 47 
patients received alternative disease-modifying antirheumatic drugs and served as the control group. The 
demographic characteristics, laboratory fi  ndings, concomitant diseases, and medication history were evaluated at 
the time of QST. Th   e cooling (CDT) and vibratory detection threshold (VDT) as the representative components of 
QST were measured.
Results  Age, gender, RA duration, ESR, and CRP did not show any signifi  cant diff  erences between the two groups. 
VDT did not demonstrate any signifi  cant diff  erence in both groups. However, CDT in LEF group was signifi  cantly 
higher than that of the control group (8.6±2.7 in LEF vs. 5.6±3.8 in control). The proportion of RA patients in 
the LEF group showing abnormally high CDT was over 2 times greater than that of the control group, but these 
fi  ndings were not statistically signifi  cant. Age, RA duration (or LEF medication in LEF group), ESR, and CRP did 
not show signifi  cant correlation with CDT in both groups. VDT signifi  cantly correlated with age in both groups.
Conclusion  LEF treatment in patients with RA may lead to abnormal CDT in QST. CDT value was not aff  ected by 
age, RA duration, disease activity, or LEF duration. It remains to be determined whether QST may be a valuable 
non-invasive instrument to evaluate the early sensory changes in patients with RA taking LEF.
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INTRODUCTION
Leflunomide (N-(4-trifluoromethylphenyl)-5-me-
thylisoxazol-4-carboxamide, LEF) is absorbed through 
the intestinal walls and converted into A77 1726 in the 
liver, inhibiting dihydrooratate dehydrogenasewhich is 
required for biosynthesis of pyrimidine nucleotide by T 
lymphocytes.
1 Then, it inhibits the production of tumor 
necrosis factor, interleukin 1, reactive oxygen radicals 
and matrix metalloproteinase 3 in synovial cells.
2,3
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According to treatment guidelines of American College 
of Rheumatology, LFE is, together with methotrexate 
(MTX), recommended as the primary drug for rheuma-
toid arthritis (RA), regardless of disease duration or activ-
ity, and combination therapy with biological products is 
also recommended if LEF monotherapy does not work.
4 
Adverse events of LEF such as diarrhea, liver toxicity, alo-
pecia, rash, hypertension and drug induced pneumonia 
have been known
5-9 however, some cases have recently 
reported peripheral polyneouropathic symptoms such as 
tingling sensation, paresthesia and motor weakness.
10-12 
In a nerve conduction study (NCS) on patients that com-
plained of peripheral neuropathic symptoms after LEF 
administration, it was found that such symptoms were 
not associated with the NCS results and it was similar to 
that observed in patients with diabetes mellitus who are 
normal with regards to NCS results but have pain, as well 
as signs and symptoms of nerve injury.
13,14 This may be 
because NCS is the test that is usedto determine the func-
tion of large myelinated fi  bers. On the other hand, quan-
titative sensory testing (QST) is the test that quantifies 
the threshold of vibration and thermal sensation so that 
it may distinguish the function of large myelinated fi  bers 
from that of small myelinated fibers and unmyelinated 
fi  bers as well as determine the function of large myelin-
ated fibers. Therefore, QST is used to diagnose diverse 
neuropathies and also complements NCS for diagnosis of 
diabetic neuropathy that is normal for NCS results.
15
In this study, we used QST to determine whether there 
is LEF-induced peripheral nerve injury and to attempted 
to elucidateits risk factors, in order to provide a key for 
RA treatment decisions. 
MATERIALS AND METHODS
Subjects
This study was approved by Hanyang University Hos-
pital’s Institutional Review Board (IRB). We studied 47 
patients that met the RA diagnostic criteria
16 published 
by American College of Rheumatology in 1987 and who 
received LEF (the treatment group). As the control group, 
another 47 patients with RA were selected that did not 
take LEF, were treated with disease-modifying anti-rheu-
matic drug (DMARD) and whose sex, age and disease 
duration were similar to the treatment group.
Before QST, a survey was performed to evaluate the sex, 
age, tingling sensation, disease duration of RA, medica-
tion in the last 6 months, concomitant disease, history 
of anticancer therapy, ESR, CRP, and the positive rate of 
rheumatoid factor (RF) and anti-CCP antibody in both 
groups. In addition the duration of LEF administration 
in the treatment group was also determined. Next we 
examined ESR and CRP as blood markers refl  ecting dis-
ease activity of RA. The whole number of normal ESR 
was reported and 0.15 mg/dl where less than 0.3 mg/dl 
of CRP was reported. To investigate other reasons which 
may cause peripheral neuropathy, we studied the his-
tory of anticancer therapy and of administration of statin 
drug, losartan, isoniazid, warfarin and tamoxifen as well 
as DMARD (hydroxychloroquine, sulfasalazine, MTX, cy-
closporine, tacrolimus, tumor necrosis factor inhibitor), 
corticosteroid and NSAIDs; for concomitant diseases, 
and examined the history of diabetes and thyroid disor-
ders.
17
QST test
QST was performed on the back of the left hand by us-
ing CASE IV QST system (WR Medical Electronics Co., 
Stillwater, USA) and the test room was maintained at 21-
23
oC. Vibratory detection threshold (VDT) was measured 
reflecting the function of large myelinated fibers, and 
cooling detection threshold (CDT) refl  ecting that of small 
myelinated fi  bers or unmyelinated fi  bers.
Th   e measurement of CDT and VDT has been described 
in detail previously by Lee and Kim
18 Briefly, for CDT, a 
stimulator (10 cm
2 of area) was attached on the dorsum 
of the first metacarpal of the left hand and the subject 
pressed either a ‘yes’ or ‘no’ button for what they recog-
nized when pyramid type cold stimulation (25 steps) was 
given. Just noticeable diff  erence (JND) which is the mini-
mal diff  erence when the subject diff  erentially recognizes 
two stimulations of similar intensity was defined as the 
stimulation intensity. Readings started from 13 JND (me-
dium intensity) and the maximum intensity was given 
for 10 seconds at 8
oC, which is not harmful to the human 
body. According towhether the subject recognized the 
initial stimulation, JND was increased or decreased by 4, 
and was changed by 2 and 1 in the second and third stim-
ulation, respectively. In this way, 25 steps of stimulation 
were given through 4-2-1 stepping algorithm, regardless 
of its order. Of these, 5 stimulations were described as 
fakes. The detection threshold was the mean of turning 
points that 1 JND increased or decreased in the 4-2-1 
stepping algorithm.LEF on Cold and Vibratory Sensation in RA
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For VDT, a vibrator of vibration transmitter was at-
tached on the dorsum of distal interphalangeal jointof 
the left hand middle fi  nger, and 125 Hz of sine-wave vi-
brations (25 steps) were given to the subject. According 
to whether the subject noticed vibration, the intensity 
was measured through a 4-2-1 stepping algorithm, as 
mentioned above.
18 In case of less than 1 JND, it could be 
considered as 0 that the subject does not recognize any 
diff  erence between stimulations; however, it was consid-
ered as 0.9 for conservative analysis.
We carried out QST on both hands in 46 of the total of 
47 patients in the control group; CDT and VDT was mea-
sured on both hands and was highly correlated. There-
fore, QST was performed on the left hand in the LEF 
treatment group.
Statistical analysis
To compare CDT, BDT and other clinical findings be-
tween the treatment and control groups, we used Mann-
Whitney rank sum test and conducted chi-square or 
Fisher Exact test to analyze the diff  erence in the number 
of patients (normal vs. abnormal). Pearson correlation 
analysis was used to examine the correlation between 
CDT and VDT, as well as disease duration of RA, duration 
of LEF administration, and ESR or CRP. To analyze the ef-
fect of LEF administration history on CDT and VDT while 
calibrating the eff  ect of other variables, analysis of cova-
riance was used. SPSS version 18.0 (SPSS Inc., Chicago, 
USA) was used for these statistical tests, and p<0.05 level 
of statistical signifi  cance was applied.
RESULTS
Patient characteristics
In the treatment group, the mean age was 52.5 years 
old; 43 females and 4 males; 10.6 years of the mean dis-
ease duration; and, 36.6 mm/hr and 0.8 mg/dl of ESR 
and CRP, respectively. In the control group, the mean 
age was 55.0 years old; 44 females and 3 males; 9.2 years 
of the mean disease duration; 28.7 mm/hr and 0.5 mg/
dl of ESR and CRP, respectively. There was no statisti-
cally signifi  cant diff  erence in the positive rate of RF and 
anti-CCP antibody, concomitant disease, and the ratio of 
corticosteroid andNSAIDs administration over 5 mg daily 
(Table 1). Th   ere were 5 patients with tingling sensation in 
the treatment group; they complained of mild symptom 
intensity on their hand and foot and their CDTs were nor-
mal, whereas two of them showed higher range of VDT.
In case of DMARD administration in the last 6 months 
before QST, the control group received medication other 
than LEF; hydroxychloroquine and sulfasalazine were 
widely used. Th   e ratio of MTX administration was similar 
in both groups. Besides, no statistically signifi  cant diff  er-
ence was observed in the administration ratio of statin 
drug, anticancer drug, losartan, isoniazid, warfarin and 
tamoxifen between the two groups.
QST results
The mean VDT of the treatment and control groups 
were 10.8±3.8 and 11.4±2.3, respectively; no significant 
diff  erence was observed between two groups (p=0.731). 
On the other hand, the mean CDT of the treatment group 
was 8.6±2.7, signifi  cantly higher than that of the control 
group (5.6±3.8) (p<0.001) (Table 2).
Based on the normal CDT range (7.3±3.3) measured in 
the same way in the Korean healthy control group by Lee 
and Kim,
18 there were 11 patients (23.4%) with abnormal 
CDT in the treatment group who showed more than 10.6 
of CDT; it was higher than that in the control group (4 
patients, 8.5%) - no statistically signifi  cant diff  erence was 
observed (p=0.089).
In Pearson correlation analysis to examine the eff  ect of 
age, disease duration of RA, duration of LEF administra-
tion, ESR and CRP on VDT and CDT in both groups, a sig-
nifi  cant correlation was observed only between age and 
VDT in both groups (controlgroup; r=0.396, p=0.00581, 
LEF treatment group; r=0.310, p=0.0337). With analysis of 
covariance to calibrate the possible eff  ect of age, disease 
duration of RA, and ESR and CRP (representing the de-
gree of inflammatory response) on peripheral nerves of 
RA patients, individual covariants were set and there was 
a signifi  cant diff  erence in CDT between the two groups, 
but not in VDT (Table 3).
DISCUSSION
LEF was approved by US FDA in September 1998 and 
is a type of DMARD with an efficiency similar to MTX. 
Its adverse events include diarrhea, liver toxicity, hyper-
tension, rash, alopecia and drug induced pneumonia;
5-9 
however, in post marketing survey, peripheral polyneu-
ropathy was not been reported. In 2002, Carulli and Da-
vies fi  rst reported the occurrence of peripheral neuropa-
thy related to LEF in two patients,
19 and subsequently, Hyung Kuk Kim, et al.
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several case reports were published abroad;
10-12 in Korea, 
Kim et al.,
20 first reported LEF-caused peripheral poly-
neuropathy in 2008.
After several case reports were presented, a cohort 
study was performed, demonstrating that LEF induces 
peripheral neuropathy.
3,21 It has been known that LEF 
inhibits the biosynthesis of uridine which is important 
in phase II conjugation such that it leads to the accu-
mulation of toxic metabolites in the body, causing LEF-
induced neuropathy.
2,22 Symptoms appear after 6-10 
months of administration on average.
21 In case of LEF-
induced peripheral polyneuropathy, however, clinical 
symptoms are unrelated to NCS results, suggesting that 
NCS is not suffi   cient to diagnose it.
13,14
Th   e most important aspects in diagnosis of peripheral 
polyneuropathy are clinical symptoms and physical fi  nd-
ings. These are subjective and qualitative, which is why 
NCS, being objective and quantitative,has been widely 
used. NCS mostly presents the function of large myelinat-
ed fi  bers; therefore, it does not correctly measure various 
neurotic symptoms that commonly occur by dysfunction 
of smallmyelinated or unmyelinated fibers in patients 
with polyneuropathy. In comparison, QST concurrently 
measures both thermal and vibration sensation and 
Table 1. Patient Characteristics in the Control and Lefl  unomide Group in Patients with Rheumatoid Arthritis
Control group LEF group p
Demographics
Number of subject 47 47
Sex (F : M) 44 : 3 43 : 4 1.000
Age (yrs) , M±SD 55.0±10.3 52.5±9.5 0.215
RA Duration (yrs), M±SD 9.2±5.9 10.6±7.4 0.450
Tingling sensation, n (%)    0 (0)          5 (10.6) 0.056
Laboratory fi  ndings
ESR (mm/hr) , M±SD 28.7±18.2   36.6±30.0 0.406
CRP (mg/dl) , M±SD 0.5±0.7   0.8±1.5 0.421
Rheumatoid factor (+), n (%)        46 (97.9)        41 (87.2) 0.111
Anti-CCP (+), n (%) 34/36 (94.4) 34/36 (94.4) 1.000
Not done: 11 Not done: 11
Concomitant diseases
Diabetes mellitus, n (%)        1 (2.1)        2 (4.3) 1.000
Hypothyroidism, n (%)    0 (0)        3 (6.4) 0.242
Medication
Chemotherapy, n (%)    0 (0)    0 (0) 1.000
Statin, n (%)          5 (10.6)          9 (19.1) 0.386
Losartan, n (%)    0 (0)        1 (2.1) 1.000
Methotrexate, n (%)        41 (87.2)        39 (83.0) 0.772
Hydroxychloroquine, n (%)        32 (68.1)    0 (0) <0.001
Sulfasalazine, n (%)        25 (53.2)        1 (2.1) <0.001
Cyclosporin, n (%)        3 (6.4)        1 (2.1) 0.617
Tacrolimus, n (%)        2 (4.3)    0 (0) 0.495
Prednisolone ≥ 5 mg/d, n (%)        13 (27.7)        21 (44.7) 0.133
NSAID, n (%)        36 (76.6)        42 (89.4) 0.170
Warfarin, n (%)    0 (0)        1 (2.1) 1.000
Tamoxifen, n (%)    0 (0)    0 (0) 1.000
Isoniazid, n (%)    0 (0)        1 (2.1) 1.000
LEF: Lefl  unomide, RA: Rheumatoid arthritis, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, Anti-CCP: 
Anti-cyclic citrullinated peptide, NSAID: Non-steroidal anti-infl  ammatory drugLEF on Cold and Vibratory Sensation in RA
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complement NCS.
18
In this study, the mean CDT (8.6±2.7) in the treatment 
group was signifi  cantly higher than that (5.6±3.8) in the 
control group. This suggests the possibility that small 
myelinated or unmyelinated fi  bers which are in charge of 
thermal sensation are damaged in the treatment group, 
compared to the control group. Based on the normal 
CDT range (7.3±3.3) of 22 healthy people (mean age: 
45.9±10.1; male : female=12 : 10) measured in the same 
way by Lee and Kim,
18 the number of patients that are 
higher than the normal CDT range in the treatment group 
was more than twofold compared to the control group. 
However, no statistically significant difference in Fisher 
exact test was observed. Th   us, as described in this study, 
the treatment group showed higher mean CDT and more 
patients measured in the abnormal range, compared to 
the control group. However, it is hard to say that there 
may be more patients with peripheral neuropathy in the 
treatment group. It is required to assure the meaningful-
ness of QST by comparing with RA patients who do not 
receive DMARD or healthy people. Also, 10.6 of CDT 
which is the lower limit of abnormally high CDT range 
is not the cut-off   value obtained from receiver operating 
characteristic (ROC) curve, but is greater than standard 
deviation by 2 on average. Th   is could be very conserva-
tive for abnormality which implies we may consider the 
possibility of lower difference in the ratio of abnormal 
vs. normal range between the two groups. Furthermore, 
the cut-off   value for individual sensory thresholds in QST 
needs to be assessed by using ROC curve.
Th   ere was no signifi  cant diff  erence in VDT betweenthe 
two groups, suggesting that there may be less possibility 
that large myelinated fi  bers that are in charge of vibration 
are damaged. No significant difference in VDT between 
two groups is similar to previous results that NCS has a 
limitation in diagnosis of LEF-induced neuropathy. It is 
thought that NCS or VDT are used to evaluate the func-
tion of large myelinated fi  bers and that LEF does not af-
fect large myelinated fi  bers.
Th   e duration of LEF administration did not aff  ect CDT 
and there was no significant correlation between CDT 
and age, disease duration of RA and RA disease activity 
in both groups. Th   is demonstrates that the accumulation 
of LEF-induced peripheral nerve injury does not happen 
as the administration duration, disease duration of RA or 
RA disease activity is increased. Such a result is similar to 
that of a previous study, in which it was shown that dis-
ease duration of RA and duration of LEF administration 
are not risk factors causing neuropathy in LEF-admin-
istered patients; however, it is diff  erent from the fi  nding 
that old age is the risk factor.
21
In this study, the small sample size is a limitation by; 
however, the diff  erence in results between two groups is 
reliable because QST is used to quantify and compare the 
mean values. It may be necessary for further study to in-
crease the sample size to calculate the prevalence rate of 
LEF-induced peripheral polyneuropathy and to perform 
both NCS and QST to provide accurate diagnostic stan-
dards for LEF-induced peripheral polyneuropathy.
CONCLUSION
Where LEF is administered to RA patients, it may lead to 
abnormal results of QST, especially CDT. Th   is means that 
there is the possibility of LEF-induced peripheral poly-
neuropathy, which It is not aff  ected by disease duration 
of RA, RA disease activity and duration of LEF admin-
istration. Further study may be necessary to determine 
whether QST is useful for the diagnosis of LEF-induced 
Table 2. Differences of Sensory Threshold between 
the Control and Leflunomide Group in Patients with 
Rheumatoid Arthritis
Control group LEF group p
CDT, M±SD   5.6±3.8   8.6±2.7 <0.001
VDT, M±SD 10.8±3.8 11.4±2.3 0.731
LEF: Leflunomide, CDT: Cooling detection threshold, 
VDT: Vibratory detection threshold
Table 3. Results of Analysis of Covariance between 
the Control and Leflunomide Group in Patients with 
Rheumatoid Arthritis
Co-variation Dependent variation F p
Age
CDT
22.540 <0.001
RA duration 20.427 <0.001
ESR 21.345 <0.001
CRP 21.494 <0.001
Age
VDT
0.065 0.799
RA duration 0.111 0.739
ESR 0.428 0.791
CRP 0.643 0.913
RA: Rheumatoid arthritis, ESR: Erythrocyte sedimenta-
tion rate, CRP: C-reactive protein, CDT: Cooling detec-
tion threshold, VDT: Vibratory detection thresholdHyung Kuk Kim, et al.
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peripheral polyneuropathy.
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